Cited by 642Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and ManagementImmunotherapy and Immune Responses

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Johnson, Douglas B., Sullivan, Ryan J., Ott, Patrick A., Carlino, Matteo S., Khushalani, Nikhil I., Ye, Fei, Guminski, Alexander, Puzanov, Igor, Lawrence, Donald P., Buchbinder, Elizabeth I., Mudigonda, Tejaswi, Spencer, Kristen, Bender, Carolin, Lee, Jenny, Kaufman, Howard L., Menzies, Alexander M., Hassel, Jessica C., Mehnert, Janice M., Sosman, Jeffrey A., Long, Georgina V., Clark, Joseph I.·2016·JAMA Oncology

DOI 10.1001/jamaoncol.2015.4368

Open this paper in CoChat — free account

Abstract

IMPORTANCE: Ipilimumab and other immune therapies are effective treatment options for patients with advanced melanoma but cause frequent immune-related toxic effects. Autoimmune diseases are common, and the safety and efficacy of ipilimumab therapy in patients with preexisting autoimmune disorders is not known. OBJECTIVE: To determine the safety and efficacy of ipilimumab therapy in patients with advanced melanoma with preexisting autoimmune disorders. DESIGN, SETTING, AND PARTICIPANTS: Retrospective review of patients with advanced melanoma and preexisting autoimmune disorders who received ipilimumab at 9 academic tertiary referral centers from January 1, 2012, through August 1, 2015. The data analysis was performed on August 24, 2015. EXPOSURE: Ipilimumab therapy. MAIN OUTCOMES AND MEASURES: Safety, in terms of frequency of autoimmune flares and conventional immune-related adverse events (irAEs), and efficacy, in terms of response rates and overall survival, were evaluated descriptively. RESULTS: Of the 30 patients who received ipilimumab (17 [57%] male; median [range] age, 59.5 [30-80] y), 6 had rheumatoid arthritis, 5 had psoriasis, 6 had inflammatory bowel disease, 2 had systemic lupus erythematosus, 2 had multiple sclerosis, 2 had autoimmune thyroiditis, and 7 had other conditions. Thirteen patients (43%) were receiving immunosuppressive therapy at the time of initiation of ipilimumab therapy, most commonly low-dose prednisone or hydroxychloroquine. With ipilimumab treatment, 8 patients (27%) experienced exacerbations of their autoimmune condition necessitating systemic treatment; all were managed with corticosteroids. Conventional grade 3 to 5 irAEs occurred in 10 patients (33%) and were reversible with corticosteroids or with infliximab therapy in 2 cases. One patient with baseline psoriasis died of presumed immune-related colitis after a 1-week delay prior to reporting symptoms. Fifteen patients (50%) had neither autoimmune disease flares nor irAEs. Six patients experienced an objective response (20%), including 1 with a durable complete response. CONCLUSIONS AND RELEVANCE: To our knowledge, this is the largest series of patients with preexisting autoimmune disease treated with immune checkpoint inhibitors. Ipilimumab was clinically active and was associated with exacerbations of autoimmune disease and conventional ipilimumab-induced irAEs that were readily manageable with standard therapies when started in a timely fashion. Ipilimumab therapy may be considered in this setting with vigilant clinical monitoring.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2015.4368

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citation
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citation
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
The mortality of rheumatoid arthritis
Wolfe, F., Mitchell, D. M., Sibley, J. T., Fries, J. F., Bloch, D. A., Williams, C. A., Spitz, P. W., Haga, M., Kleinheksel, S. M., & Cathey, M. A. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370408 · Cited by 1,325
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262

Show all 30 references

Sorted by citations

Items 501–600 of 639

Immune-checkpoint inhibitor anti-PD1 aggravates colitis-associated colorectal cancer without enhancing intestinal inflammation
Collard, M. K., Guedj, N., Tourneur‐Marsille, J., Albuquerque, M., Maggiori, L., Hammel, P. R., Tréton, X., Panis, Y. H., & Ogier‐Denis, É. (2020) · Integrative Cancer Science and Therapeutics · doi:10.15761/icst.1000334 · Cited by 3
Immunosuppressive therapy management in cancer patients with autoimmune diseases treated with immune checkpoint inhibitors: A case series and systematic literature review
Wuyts, S. C. M., Cappelle, C. A. H., Verhaert, M., Bravenboer, B., & Aspeslagh, S. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231167824 · Cited by 3
Clinical features and prognosis of lung cancer in patients with connective tissue diseases: a retrospective cohort study
Li, N., Gao, L., Bai, C., Zhao, L. B., & Shao, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1167213 · Cited by 3
Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors
Festino, L., & Ascierto, P. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_33 · Cited by 3
[Clinical Diagnosis and Treatment Recommendations for Adverse Reaction in the Nervous System Related to Immunocheckpoint Inhibitor].
Shi, J., Niu, J., Shen, D., Li, Y., Liu, M., Tan, Y. K., Cui, L., Guan, Y., & Zhang, L. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.10.05 · Cited by 3
The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.
Shah, N., Sandigursky, S., & Mor, A. (2017) · PubMed · Cited by 3
Management einer persistierenden Kolitis nach erfolgreicher Immuntherapie eines nicht-kleinzelligen Karzinoms der Lunge
Zellweger, M., Rogler, G., Komminoth, P., Werth, L., & Breidert, M. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1652-2638 · Cited by 3
Prediction of immune checkpoint blockade‐related hepatitis in metastatic melanoma patients
Schilling, H., Hutchinson, J. A., & Haferkamp, S. (2022) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14726 · Cited by 3
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials
An, J., Han, S., Kim, H. I., & Shim, J. H. (2022) · Hepatology Communications · doi:10.1002/hep4.2025 · Cited by 3
Immune checkpoint inhibitor associated ocular hypertension (from presumed trabeculitis)
Canestraro, J., Do, A., Potash, S. D., Panarelli, J. F., Berkenstock, M., Abramson, D. H., & Francis, J. H. (2021) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2021.101125 · Cited by 3
Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions
Pan, W., Zhao, J., Zhang, S., Chen, X., Liang, W., & Li, Q. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108337 · Cited by 3
Glioblastoma in Patients With Multiple Sclerosis
Berkman, J. M., Nakhate, V., & Castro, L. N. G. (2022) · The Neurohospitalist · doi:10.1177/19418744221106003 · Cited by 4
Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma
Pavlick, A. C., & Weber, J. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_60 · Cited by 3
Underlying Autoimmune Disease Is Not a Contraindication to the Use of Ipilimumab
Disis, M. L. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4717 · Cited by 3
Is Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer?
Buckley, L. M., & Suarez-Almazor, M. E. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41064 · Cited by 3
Managing cancer in autoimmune patients: Overcoming therapeutic challenges and expanding treatment options
Singh, S., & Das, A. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156212 · Cited by 2
El español de los territorios del noroeste
Martínez, J. A. (1995) · Studia Academica: Revista de Investigación Universitaria · Cited by 2
Gibt es eine Überbehandlung von Melanompatienten am Ende ihres Lebens? Ergebnisse einer multizentrischen Studie an 193 Melanompatienten
Forschner, A., Loquai, C., Meiß, F., Hüning, S., Pawlowski, J., Bradfisch, F., Lehr, S., & Nashan, D. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14501_g · Cited by 2
Clinical Features and Management of Dermatologic Immune-Related Adverse Events for the Inpatient Dermatologist
Fay, C. J., Iriarte, C., Allais, B. S., Pisano, C. E., Jfri, A. H., Larocca, C. A., & LeBoeuf, N. R. (2023) · Current Dermatology Reports · doi:10.1007/s13671-023-00395-8 · Cited by 2
Stage 4 Non-small Cell Lung Cancer With Human Epidermal Growth Factor Receptor 2 Alterations and Myocarditis Induced by Immune Checkpoint Inhibitors: A Case Report
Abulnaja, R. (2023) · Cureus · doi:10.7759/cureus.48859 · Cited by 2
Pathological Complete Response to Pembrolizumab plus Axitinib Combination following Serious Immune-Related Adverse Events in an Advanced Renal Cell Carcinoma Patient with a History of Rheumatoid Arthritis
Bergamini, M., Volta, A. D., Valcamonico, F., Caramella, I., Buffoni, M., Munari, E., Fisogni, S., Zanotelli, T., Suardi, N. R., & Berruti, A. (2024) · Case Reports in Oncology · doi:10.1159/000535460 · Cited by 2
Pembrolizumab-induced nephrotoxicity in a patient with breast cancer
Alkassis, S., Fitzsimmons, K. C., & Hurvitz, S. A. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241248362 · Cited by 2
Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma
Tenstad, H. B., Ruhlmann, C. H. B., Möller, S., Kjaer, S., Bastholt, L., Just, S. A., & Lindegaard, H. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103400 · Cited by 2
Myocarditis Induced by Immunotherapy in Metastatic Melanoma—Review of Literature and Current Guidelines
Czarnecka, A. M., Kleibert, M., Płachta, I., Rogala, P., Wągrodzki, M., Leszek, P., & Rutkowski, P. L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175182 · Cited by 2
Inflammatory Bowel Disease and Colorectal Cancer: An Eternal Fire in a Beautiful Garden
Koyyala, V. P. B., Kantharia, C. V., Darooka, N., Kumar, M., Ranjan, P., Anikhindi, S. A., Bansal, N. K., Sharma, P. K., BHALLA, V., Kumar, M., et al. (2024) · South Asian Journal of Cancer · doi:10.1055/s-0045-1802335 · Cited by 2
Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers
Beg, M. S., & Meyer, J. J. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.06.17 · Cited by 2
Immune Checkpoint Inhibition
Sammons, S. L., McNamara, M. A., Salama, A. K. S., & Crawford, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_12 · Cited by 2
Pertinence des inhibiteurs des points de contrôle immunitaire chez les patients atteints de maladie auto-immune ou inflammatoire
Danlos, F., & Lambotte, O. (2018) · médecine/sciences · doi:10.1051/medsci/20183406007 · Cited by 2
PD-1 Inhibitor Therapy in a Patient with Preexisting P-ANCA Vasculitis: A Case Report and Review of the Literature
Ramos, A., Carmen, M. G. D., & Yeku, O. (2020) · Case Reports in Oncological Medicine · doi:10.1155/2020/3428945 · Cited by 2
Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases
Kubiatowski, T., Nicoś, M., & Krawczyk, P. A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568081 · Cited by 2
Immune Checkpoint Inhibitors - New Insights and Recent Progress
Raza, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100958 · Cited by 2
Anti-synthetase syndrome-associated interstitial lung disease possibly caused by atezolizumab in a patient with lung adenocarcinoma: a case report
Miyamoto, I., Shimizu, T., Kusahana, R., Nomoto, M., Fujiwara, D., Nishizawa, T., Hayashi, K., Nakagawa, Y., & Gon, Y. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02446-z · Cited by 2
Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitor Therapy: A Comprehensive Review
Chitsazan, M., Amin, A., Ladel, L., Baig, A., & Chitsazan, M. (2023) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000327 · Cited by 2
Immunotherapy for epithelial tumors of the thymus
Kit, O. I., Kharagezov, D. A., Lazutin, Y. N., Арменовна, М. Э., Milakin, A. G., Stateshny, O. N., Ayrapetova, T. G., Leyman, I. A., Gappoeva, M. A., Vitkovskaya, V. N., et al. (2023) · South Russian Journal of Cancer · doi:10.37748/2686-9039-2023-4-3-7 · Cited by 2
Toxicities in Immune Checkpoint Inhibitors
Lee, S. S., Loecher, M., & Puzanov, I. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00011-1 · Cited by 2
Self-citation
Immune-related adverse events from immune checkpoint inhibitors: Review of risk factors in clinical practice
Meanwatthana, J. (2020) · Pharmaceutical Sciences Asia · doi:10.29090/psa.2020.02.019.0095 · Cited by 2
Anti-PD-1 Monotherapy Versus Anti-PD1 Plus Anti-CTLA4 in Advanced Melanoma: How do we Decide?
Au, L., O’Reilly, A., & Larkin, J. (2017) · Melanoma Management · doi:10.2217/mmt-2017-0016 · Cited by 2
Metastatic Melanoma Treatment in Special Populations
Miceli, M., Boatwright, C., & Mehnert, J. M. (2024) · The Cancer Journal · doi:10.1097/ppo.0000000000000701 · Cited by 1
Self-citation
Immunotherapy-induced hepatitis in metastatic colorectal cancer: a systematic review and meta-analysis
Saowapa, S., Polpichai, N., Tanariyakul, M., Wannaphut, C., Wattanachayakul, P., Danpanichkul, P., Suenghataiphorn, T., Kulthamrongsri, N., Siladech, P., & Tijani, L. (2024) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2024.2374161 · Cited by 1
Tislelizumab-induced hemophagocytic lymphohistiocytosis in a patient with microsatellite instability-high colon cancer and coexisting systemic lupus erythematosus: a case report and literature review
Jiao, P., Wang, S., Wu, J., Zhao, Y., Han, J., & Sha, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1585133 · Cited by 3
Preexisting ulcerative colitis increases the risk of immune-related colitis and predicts divergent survival outcomes in gastrointestinal cancer patients treated with immune checkpoint inhibitors
Xu, S., Chen, L., Liu, K., Tao, H., Ji, Z., Wu, J., Zhao, Y., Zhou, Q., Li, L., Zhu, H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1627680 · Cited by 1
Immunotherapy for Melanoma in Patients with Altered Immune Systems: Unique Challenges and Clinical Considerations
Peacker, B. L., Hwang, J. C., & Hartman, R. I. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03453-8 · Cited by 1
Flare incidences of pre-existing rheumatologic diseases in patients with solid tumors receiving immune checkpoint inhibitors: A systematic review and meta-analysis
Yamada, K., Matsui, T., Takahashi, T., Nishimura, Y., & Fujiwara, Y. (2026) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2026.152938 · Cited by 1
Successful use of immune checkpoint Inhibition in a patient with myasthenia gravis and recurrent endometrial cancer- expanding access beyond initial clinical trial eligibility
Julian, O. N., Christofsen, A., & Eskander, R. N. (2026) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2026.102027 · Cited by 1
Kombinierte Immuncheckpoint-Inhibition bei inoperablem Gingivamelanom
Neumann, M., Ruppel, E., Unger, S., Zahn, A., & Ludwig‐Peitsch, W. (2019) · Aktuelle Dermatologie · doi:10.1055/a-0828-3546 · Cited by 1
Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicine
Sciascia, S., Hudson, M., Fritzler, M. J., Satoh, M., & Mähler, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820239-5.00011-5 · Cited by 1
Sjekkpunkthemmerindusert myokarditt
Gulati, G., Tjessem, K. H., Horndalsveen, H., Halvorsen, S., & Haakensen, V. D. (2022) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.21.0817 · Cited by 1
Incidence and risk factors for neoplasia in inflammatory bowel disease
Garcia, J. L., Rosa, I., da Silva, J. P., Moleiro, J., & Claro, I. (2023) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13908 · Cited by 1
Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li, H., Huntington, S. F., Gross, C. P., & Wang, S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300789 · Cited by 1
Multiple Options: How to Choose Therapy in Frontline Metastatic Melanoma
Kennedy, L. B., & Salama, A. K. S. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01547-0 · Cited by 1
Entscheidungsfindung für die klinische Praxis: Aktuelle Konzepte und Behandlungsalgorithmen mit Immun-Checkpoint-Inhibitoren beim Melanom
Schadendorf, D. (2016) · Oncology Research and Treatment · doi:10.1159/000449458 · Cited by 1
New Anticancer Immunotherapies: Implications for Physical Therapy
Tabares, T., Unmack, T., Calys, M., & Stehno‐Bittel, L. (2018) · Rehabilitation Oncology · doi:10.1097/01.reo.0000000000000144 · Cited by 1
Immune Checkpoint Inhibitor Related Neuropathic Adverse Effects on Cancer Patients
Khanal, S., & Zhang, H. (2019) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2019.76001 · Cited by 1
Gastrointestinal side effects of immune checkpoint inhibitors: new topic for gastroncologists
Paydaş, S. (2019) · Hematology & Medical Oncology · doi:10.15761/hmo.1000181 · Cited by 1
A Case of Malignant Melanoma Associated with Polymyositis Treated with Immune Checkpoint Inhibitors
Nomura, H., Yamasaki, O., Kaji, T., WAKABAYASHI, H., Miyawaki, Y., & Morizane, S. (2019) · The Nishinihon Journal of Dermatology · doi:10.2336/nishinihonhifu.81.396 · Cited by 1
Nephrotoxicity in patients receiving immune checkpoint inhibitors
Chuva, T. (2020) · Portuguese Journal of Nephrology & Hypertension · doi:10.32932/pjnh.2020.01.047 · Cited by 1
Complications neurologiques des immunothérapies anti-cancéreuses : une pathologie émergente
Joubert, B. (2020) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2020.01.012 · Cited by 1
Side effects and management in immunotherapy based on immune checkpoint inhibitors
Li, W., Li, L.-C., & Huo, J.-G. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i16.755 · Cited by 1
A flare-up of rheumatoid arthritis followed by adrenocorticotropic insufficiency induced by pembrolizumab: A case-report
Garon-Czmil, J., Abs, D., Granel‐Brocard, F., Gillet, P., & Yelehe‐Okouma, M. (2020) · Therapies · doi:10.1016/j.therap.2020.11.005 · Cited by 1
Sarcoidosis reactivation with immune checkpoint inhibitors
Creusot, Q., Pamart, G., Mennecier, B., Matau, C., Robert, C., Mascaux, C., & Quoix, É. (2020) · Cancer Reports and Reviews · doi:10.15761/crr.1000218 · Cited by 1
Relato de caso – eventos neuromusculares relacionados com inibidores de checkpoint
Borges, M. Q., Dias, E. C. R., Neto, Z. A. D. S., Guedes, M. R., Prado, Á. P., & Carneiro, M. A. D. (2022) · Revista Neurociências · doi:10.34024/rnc.2022.v30.12780 · Cited by 1
Toxicities from immunotherapy: From clinical trials to real-world clinical practice
Riveiro‐Barciela, M., Araguás, E. T., Martínez‐Valle, F., Roca-Herrera, M., Zamora, E., Barreira‐Díaz, A., & Muñoz‐Couselo, E. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.06.030 · Cited by 1
The predictive potential of autoimmune-inflammatory syndrome induced by adjuvants (ASIA) criteria to assess the risk of adverse events and efficacy of immune checkpoint inhibitor therapy
Zhukova, N. V., Орлова, Р. В., Malkova, A. M., Каледина, Е. А., Demchenkova, A., Percik, R., & Shoenfeld, Y. (2022) · Immunologic Research · doi:10.1007/s12026-022-09304-w · Cited by 1
Dermatology (Skin)
Brown, A. M., Masterson, W. M., & Patel, A. B. (2022) · Springer eBooks · doi:10.1007/978-3-031-00241-0_3 · Cited by 1
Clinical Outcome of Function-Limiting Immune Arthropathy during Checkpoint Inhibitor Therapy: A Case Series
Chaffin, K., & Samlowski, W. E. (2023) · Annals of Case Reports · doi:10.29011/2574-7754.101384 · Cited by 1
Deterioration in multifocal motor neuropathy upon treatment of immune-related adverse events of checkpoint inhibition
Kleinveld, V. E. A., Wanschitz, J., Löscher, W. N., Hotter, A., & Horlings, C. G. C. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2342238 · Cited by 1
Respiratory Complications
Shannon, V. R., Eapen, G. A., Jiménez, C. A., Grosu, H. B., Morice, R. C., Bashoura, L., Sheshadre, A., Evans, S. E., Adachi, R., Kroll, M. H., et al. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm134.pub2 · Cited by 1
Checkpoint Inhibitor-Associated Autoimmunity: What a Rheumatologist Needs to Know.
Ghosh, N., & Bass, A. R. (2022) · PubMed · doi:10.1097/rhu.0000000000001209
Ipilimumab trotz Autoimmunerkrankung?
Schumacher, B. (2016) · Im Focus Onkologie · doi:10.1007/s15015-016-2475-4
Systemtherapie des inoperabel metastasierten malignen Melanoms
Gutzmer, R., Rauschenberg, R., & Meier, F. E. (2016) · Der Hautarzt · doi:10.1007/s00105-016-3795-1
Checkpoint-Inhibitor trotz Autoimmunerkrankung
Schumacher, B. (2016) · hautnah dermatologie · doi:10.1007/s15012-016-2133-8
Wie sicher ist Ipilimumab?
Schumacher, B. (2016) · Info Onkologie · doi:10.1007/s15004-016-5222-2
Better use of immune checkpoint inhibition: Treating higher risk patients and examining neurologic toxicity
Postow, M. A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw642
When to Consider Alternatives to Front-Line Immune Therapies in Metastatic Melanoma
Wang, D. Y., & Johnson, D. B. (2017) · Melanoma Management · doi:10.2217/mmt-2017-0005
Self-citation
Complications rhumatologiques de l’immunothérapie anticancéreuse
Schaeverbeke, T., & Kostine, M. (2017) · Revue du Rhumatisme · doi:10.1016/s1169-8330(17)30327-7
Managing Checkpoint Inhibitor Symptoms and Toxicity
Pavlick, A. C., & Weber, J. S. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_60-1
Reply
Tison, A., Kostine, M., & Cornec, D. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41139
Immune disorders of the gastrointestinal tract
Bhattacharyya, J., & Kaser, A. (2020) · doi:10.1093/med/9780198746690.003.0292
Dermatological adverse events of immune checkpoint inhibitors
(2020) · American Journal of Dermatological Research and Reviews · doi:10.28933/ajodrr-2020-09-1805
Kombinierte Immuncheckpoint-Inhibition bei inoperablem Gingivamelanom
Neumann, M., Ruppel, E., Unger, S., Zah, A., & Ludwig‐Peitsch, W. (2020) · TumorDiagnostik & Therapie · doi:10.1055/a-1241-8964
Existent-ils des contre-indications à l’immunothérapie dans les cancers broncho-pulmonaires ?
Souquet, P. J., Darrason, M., Fontaine-Delaruelle, C., & Freymond, N. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(20)30154-3
Critical Analysis of Immune Checkpoint Inhibitor Immunotoxicity Management
Lopes, C., Morgado, S., Plácido, A. I., Roque, F., & Morgado, M. (2021) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00670-w
Cancer Immunotherapy in Patients with Preexisting Inflammatory Arthritis
Thanarajasingam, U., & Abdel‐Wahab, N. (2021) · Springer eBooks · doi:10.1007/978-3-030-56824-5_12
Cancer Immunotherapy in Patients with Preexisting Rheumatic Diseases: Other Rheumatic Autoimmune Diseases
Kostine, M., & Tison, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-56824-5_13
Gastrointestinal Toxicities of Immunotherapy
Gandhi, S., Gupta, A., & Ernstoff, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-67241-2.00019-7
Rheumatological Toxicities of Immunotherapy
Calabrese, C. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-67241-2.00024-0
Colitis Induced by Immune-checkpoint Inhibitors
Yanai, S., Sugai, T., & Matsumoto, T. (2021) · Nihon Daicho Komonbyo Gakkai Zasshi · doi:10.3862/jcoloproctology.74.599
Clinical Information Access Portal (CIAP) use by NSW Health staff over 15 years
Pryor, M., White, D. E., Potter, B., & Traill, R. (2013) · Studies in health technology and informatics · doi:10.3233/978-1-61499-266-0-95
El castillo-palacio de Forna
Desfilis, A. S. (1989) · Archivo de arte valenciano
Inhibition of Expression of Control Points – a Prospective Strategy in Treatment of Malignant Tumors
Костецкая, Т. В., Лемешевский, В. О., & Batyan, A. N. (2022) · Евразийский онкологический журнал · doi:10.34883/pi.2022.10.1.004
Tumour burden score and immune‐related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors
Carlo, E. D., D’Alessio, A., Cammarota, A., Zanuso, V., Pressiani, T., Bozzarelli, S., Ferrillo, G., Vatteroni, G., Pedicini, V., Giordano, L., et al. (2022) · Liver Cancer International · doi:10.1002/lci2.51
Diagnosis and treatment of paraneoplastic neurological disorders
Desjardins, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821976-8.00029-3
Ipilimumab
(2016) · Reactions Weekly · doi:10.1007/s40278-016-20703-7
Sarcoidosis
Pundole, X., Ramos‐Casals, M., & Lambotte, O. (2021) · Springer eBooks · doi:10.1007/978-3-030-56824-5_8
Vorhersage von Immuncheckpoint‐Inhibitor‐bedingter Hepatitis bei Patienten mit metastasiertem Melanom
Schilling, H., Hutchinson, J. A., & Haferkamp, S. (2022) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14726_g
The Flip of the Coin of Personalized Cancer Immunotherapy: A Focused Review on Rare Immune Checkpoint Related Adverse Effects
Omar, N. E., Afifi, H. M., Sahal, A., Mekkawi, R., & Elewa, H. F. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107833
The Use of Immunotherapy in Cancer Patients with Autoimmune Diseases
Lee, C., & Seetharamu, N. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_63
Diagnostic et traitement des complications neurologiques des immunothérapies anticancéreuses
Farina, A., & Joubert, B. (2023) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2023.01.011
Data from Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease–Associated Colorectal Cancers
Din, S., Wong, K., Mueller, M. F., Oniscu, A., Hewinson, J., Black, C. J., Miller, M. L., Jiménez-Sánchez, A., Rabbie, R., Rashid, M., et al. (2023) · doi:10.1158/1078-0432.c.6529113
Data from Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages
Valencia, J. C., Erwin-Cohen, R. A., Clavijo, P. E., Allen, C. T., Sanford, M. E., Day, C., Hess, M. M., Johnson, M., Yin, J., Fenimore, J. M., et al. (2023) · doi:10.1158/0008-5472.c.6513930.v1

Authors: Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., Mudigonda, T., Spencer, K., Bender, C., Lee, J., Kaufman, H. L., Menzies, A. M., Hassel, J. C., Mehnert, J. M., Sosman, J. A., Long, G. V., & Clark, J. I.
Affiliations: Vanderbilt University Medical Center (US)
Massachusetts General Hospital (US)
Dana-Farber Cancer Institute (US)
The University of Sydney (AU)
Roswell Park Comprehensive Cancer Center (US)
Rutgers Cancer Institute (US)
University Hospital Heidelberg (DE)
Westmead Hospital (AU)
Loyola University Medical Center (US)
Corresponding author: Johnson, Douglas B.
ORCID: Johnson, Douglas B.
Sullivan, Ryan J.
Ott, Patrick A.
Carlino, Matteo S.
Khushalani, Nikhil I.
Ye, Fei
Guminski, Alexander
Puzanov, Igor
Lawrence, Donald P.
Buchbinder, Elizabeth I.
Spencer, Kristen
Bender, Carolin
Lee, Jenny
Kaufman, Howard L.
Menzies, Alexander M.
Hassel, Jessica C.
Mehnert, Janice M.
Sosman, Jeffrey A.
Long, Georgina V.
Clark, Joseph I.
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2016-02-01
Volume: 2
Issue: 2
Pages: 234
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2015.4368
OpenAlex: W2193769500
Cited by: 642
References: 30
Citations by year: 2026: 13 · 2025: 29 · 2024: 49 · 2023: 44 · 2022: 64 · 2021: 73 · 2020: 94 · 2019: 93 · 2018: 65 · 2017: 68 · 2016: 47
FWCI: 26.20
Type: journal article
Language: en
Open access: closed
Locations: JAMA Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (K12 CA 0906525, K12CA090625)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: ipilimumab, advanced melanoma, immune-related adverse events, immune-related colitis, immune-related pneumonitis, immune-related hepatitis, immune-related endocrinopathy, immune-related dermatitis, immune checkpoint inhibitors, immunosuppressive therapy, rheumatoid arthritis, psoriasis, inflammatory bowel disease, systemic lupus erythematosus
MeSH terms: Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Autoimmune Diseases, Female, Humans, Male, Melanoma, Middle Aged, Retrospective Studies, Risk Factors, Skin Neoplasms, Time Factors, Autoimmunity, Treatment Outcome, Risk Assessment, Patient Selection, Tertiary Care Centers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks